For metastatic BC, standard treatment options include targeted approaches, such as CDK4 and CDK6 inhibitors, PI3K inhibitors, PARP inhibitors, and PD-L1 immunotherapy, depending on the type and molecular profile of the tumor [2]. This evidence concerns the gene CD274 and neoplasm.